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 “A high-powered mutant never even considered for 
mass-production. Too weird to live, too rare to die." 
 
- Hunter S. Thompson 
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ABREVIATIONS 
 
AMP adenosine monophosphate 
AMPK amp activated protein kinase 
APC adenomatous polyposis coli 
ATP adenosine triphosphate 
BMP4 bone morphogenic protein 4 
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CDK7 cyclin-dependent kinase 7 
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CPG change In polyposis grade 
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EGFR epithelial growth factor receptor 
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FGF fibroblast growth factor 
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GST glutathione S-transferase 
HCC hepatocellular carcinomas  
HGF hepatocyte growth factor 
IL-6 interleukin 6 
K14 keratin 14 
KRAS Kirsten rat sarcoma viral oncogene 
LOH loss of heterozygosity 
LSB Laemmli lysis buffer 
MARK microtubule affinity-regulating kinase 
MEF mouse embryonic fibroblast 
MLPA multiplex ligation-dependent probe amplification 
mRNA messenger ribonucleic acid 
mTOR mammalian target of rapamycin 
MVD microvessel density  
PAGE  polyacrylamide gel electrophoresis 
par-1 partitioning gene-4 
PCR  polymerase chain reaction 
PGE2 prostaglandin E-2 
PI3K phosphatidylinositol 3-kinase 
PJS Peutz-Jeghers syndrome 
RB1 retinoblastoma-1 
RT-PCR reverse transcription polymerase chain reaction 
SDS sodium dodecyl sulphate 
SIK salt-inducible protein kinase 
siRNA short interfering ribonucleic acid 
SM22 smooth muscle gene 22 / Transgelin 
SMA smooth muscle actin  
SMC smooth muscle cell 
STRAD STE20-related adaptor  
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Tagln Transgelin / SM22 
TCF transcription factor 
TGFß transforming growth factor ß 
TGFßRII  TGFß receptor 2 
Tris  hydroxymethylaminoethane 
TSC tuberous sclerosis complex 
TUNEL Terminal uridine nick-end labeling 
VEGF vascular endothelial growth factor 
wt wild type 
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ABSTRACT 
Peutz-Jeghers syndrome (PJS) is a condition characterized by gastrointestinal polyposis and 
increased risk of cancer. At the onset of this study, mutations in the LKB1 serine/threonine 
kinase had been identified in approximately half of the studied PJS patients, indicating that 
LKB1 is a tumor suppressor underlying at least a subset of PJS cases. Mice with targeted 
heterozygous deletion of Lkb1 develop gastrointestinal polyps remarkably similar to PJS 
polyps corroborating the tumor suppressor function of LKB1/Lkb1. Most importantly, the 
polyps in Lkb1+/– mouse contain a notable stromal compartment with a core of smooth 
muscle cells that is the defining characteristic of a PJS polyp. In addition, the PJS and mouse 
polyps frequently exhibit elevated cyclooxygenase-2 (COX-2), a feature also noted in other 
gastrointestinal polyposis syndromes. Despite the aforementioned characterizations, the 
molecular mechanism driving PJS polyp development has not been identified. 
As only a subset of PJS patients have been reported to harbor LKB1 mutations, mutations in 
other loci might represent an alternative cause of PJS. To characterize the genetic background 
of PJS, mutation analysis of three genes encoding LKB1 interacting proteins, BRG1, 
STRADα, and MO25α, was performed in PJS patients without identified LKB1 mutations. No 
disease causing mutations were detected in these genes. The exclusion of the studied 
candidate genes with these criteria, and the concurrent increase in frequency of detected 
LKB1 mutations does not support involvement of other loci in PJS. 
As COX-2 inhibition has been effective in suppression of familial adenomatous polyposis, 
the elevation of COX-2 in PJS polyps suggested that COX-2 inhibition could decrease PJS 
polyposis. This was investigated by genetic and pharmacological interventions that targeted 
COX-2 in the Lkb1+/– mice. In comparison to PJS modeling Lkb1+/– mice, the polyp burden 
in the Lkb1+/– mice with either mono- or biallelic deletion of COX-2 was dramatically 
reduced. Furthermore, a selective COX-2 inhibitor celecoxib efficiently suppressed the tumor 
burden in Lkb1+/– mice. COX-2 inhibition reduced particularly the incidence of the large 
(>5mm) polyps whereas the number of smaller polyps was unaffected, suggesting that COX-
2 expression is not required for polyp initiation but contributes significantly to tumor growth. 
These results prompted a pilot clinical trial with PJS patients receiving 200mg of celecoxib 
twice a day for 6 months. A subset of PJS patients (2/6) responded favorably to the celecoxib 
treatment, and a significant reduction in polyposis severity was also noted when the polyp 
grading data of all patients were combined. Together the data establish the polyposis 
promoting role of COX-2 in Peutz-Jeghers polyposis, and suggest that COX-2 inhibition is 
efficient in suppression of PJS polyposis.  
Polyp development is commonly thought to result from mutations in epithelial cells. 
However, the characteristic stroma of PJS polyps together with the suggestion that polyps can 
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retain a functional copy of Lkb1 raised the possibility of non-epithelial origin of 
tumorigenesis in PJS. To investigate this possibility, murine Lkb1 was deleted tissue 
specifically in smooth muscle cells. Both monoallelic and biallelic deletions resulted in the 
development of gastrointestinal polyps indistinguishable from PJS polyps. Moreover, 
multiplicity of tumors in the smooth muscle specific biallelic deletion was only moderately 
(1.8-fold) higher than in the monoallelic deletion, demonstrating that Lkb1 LOH in stromal 
cells is not required for polyp development. The Lkb1 deficient mesenchymal cells produced 
less TGFß, and p-Smad2 staining was reduced in epithelial cells adjacent to Lkb1 deleted 
mesenchyme. These results identified impaired TGFß signaling from mesenchyme to 
epithelium as a possible mechanism for polyp development. Consistently, the epithelial 
proliferation in tumors coincided with the reduced p-Smad2 staining and with Lkb1 
deficiency of the adjacent stroma. The TGFß signaling defect was importantly also noted in 
polyps from PJS patients, supporting the role of stroma as a major contributor to PJS 
polyposis by generation of a permissive microenvironment for epithelial expansion. 
The results of this thesis contribute to the notion that LKB1 is the only PJS gene 
substantiating the findings from the Lkb1 heterozygous mouse model of PJS. From the 
viewpoint of therapy development, the results provide proof of principle for the efficacy of 
COX-2 chemoprevention in PJS. Furthermore, the discovery of the stromal-derived 
mechanism of LKB1 tumor suppression forms a basis for the development of novel 
therapeutic interventions targeting mesenchymal signaling in PJS polyposis and possibly 
other cancers with loss of LKB1. 
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REVIEW OF THE LITERATURE 
Tumor suppressors 
Tumorigenesis is generally considered to be a consequence of mutations that will cause a cell 
to multiply pathologically. This view was first based on chromosomal abnormalities often 
noted in cancer cells, but it was the discovery of the cellular proto-oncogenes and oncogenes 
(Stehelin et al. 1976) that explained how rearrangements of DNA could result in defective 
growth control and cancer. However, many familial cancer syndromes were hard to explain 
by activated oncogenes, and the fundamental role of growth regulation was regarded too 
important to be controlled only by positive control of the oncogenes. 
The first evidence for negative growth regulators, or “anti-oncogenes” that were later termed 
tumor suppressors, came from studies on the childhood eye tumor retinoblastoma. These 
tumors occur in sporadic and familial forms. While sporadic tumors appear unilaterally, that 
is in one eye, the tumors in familial cases are present bilaterally and appear multifocal even 
within a single eye. Combining this difference with his ground braking work on the kinetics 
of tumor appearance in the hereditary and sporadic cases, Alfred Knudson concluded that 
both forms could be explained by loss of a single gene (Knudson 1971). According to his 
"two-hit" hypothesis individuals with familial cases inherit one mutated allele of this RB1 
gene and require a single additional mutation event, or a "second hit", to begin tumorigenesis. 
Correspondingly, the sporadic retinoblastomas are delayed compared to familial cases, as the 
stochastic mutation events have to inactivate both alleles of the first identified tumor 
suppressor RB1. 
Studies on many other cases of cancer have since demonstrated that progression of cancer is a 
multistep process, commonly involving sequential malfunctions in both oncogenes and tumor 
suppressors (Hahn et al. 2002). Studies on gastrointestinal polyposis syndromes, particularly 
on Familial Adenomatous Polyposis (FAP) have been most revealing in this regard. 
Gastrointestinal tumors in patients with FAP develop due to hereditary mutations in the 
Adenomatous polyposis coli (APC) tumor suppressor gene (Groden et al. 1991; Kinzler et al. 
1991). Functioning according to Knudson’s “two-hit” hypothesis, a second sporadic mutation 
of APC is noted in the tumor cells of epithelial origin (Nakamura et al. 1991). However, 
while loss of APC lays the groundwork for clonal expansion, development and progression of 
adenomas requires an additional oncogenic mutation, most commonly of KRAS (Vogelstein 
et al. 1988) (Box 1). These adenomatous polyps develop in FAP by the hundreds, but still 
only some of them progress to cancer. For this to happen, the epithelial cells typically gain 
additional inactivating mutations of tumor suppressors SMAD4 and p53 that allows for the 
accelerated clonal expansion and transformation required for cancer development (reviewed 
in Fodde et al. 2001). Importantly, loss of APC is noted in approximately 85% of both 
Review of the Literature 
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familial and sporadic colorectal cancers disregarding their stage (Kinzler et al. 1996). This 
demonstrates that the very first “nudge” toward cancer, caused by the loss of a tumor 
suppressor identified from hereditary polyposis is of utmost importance for cancer in general. 
 
 
Box 1. Model for the sequence of events occurring in colorectal cancer development.  
A. Schematic figure of factors involved with homeostasis maintenance and cancer initiation in 
the small intestine. Normally the balance of cellular proliferation and differentiation of the 
gastrointestinal epithelium is maintained by Wnt, Transforming growth factor beta (TGFß) 
and Bone morphogenetic protein (BMP) signaling. Wnt signaling is required for the rapid 
proliferation (red cells) to compensate for continuous shedding of differentiated cells (green 
cells) from the villus tip. Deregulated Wnt pathway is the hallmark of Familial adenomatous 
polyposis (FAP) where mutations in APC lead to inability to degrade Wnt mediator ß-catenin 
(reviewed in Fodde et al. 2001). As a result, APC–/– cells do not respond to reduction in Wnt 
signals that occurs while cells migrate towards the villus tip. This leads to development of an 
adenoma due to sustained Tcf/Lef mediated transcription of multiple genes involved in 
driving the cell cycle and maintaining an undifferentiated, proliferating state of cells.  
B. Development of colorectal cancer requires multiple genetic alterations. Deletions of APC 
constitute the first step towards cancer in both FAP and in 85% of non-familial colorectal 
cancers (1 hereditary and 1 sporadic mutation in FAP, and 2 sporadic mutations in non-
familial cancer). Loss of APC leads to genomic instability and typically to activation of KRAS 
oncogene and to deletions of members of the TGFß pathway, SMAD4 or TGFßR-II to drive 
tumor progression. Malignant transformation is frequently associated with mutations in the 
p53 tumor suppressor gene. Modified from Radtke et al. 2006. 
LKB1 tumor suppression in Peutz-Jeghers syndrome 
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Peutz-Jeghers Syndrome  
Peutz-Jeghers Syndrome (PJS) is a rare hereditary polyposis syndrome that was first 
described by Peutz in 1921 (Peutz 1921) and Jeghers in 1949 (Jeghers et al. 1949). The main 
characteristics of PJS are mucocutaneus pigmentation and gastrointestinal polyposis. While 
the pigmentation of the lips and mouth (sometimes also of hands and genitalia) can be quite 
distinct at infancy, it commonly fades with age. Diagnosis of PJS is made when the patient 
meets two of the following criteria: two or more gastrointestinal polyps, mucocutaneous 
pigmentation or family history of PJS (Vasen 2000).  
The most common cause of symptoms and thus diagnosis of PJS are the gastrointestinal 
polyps that manifest in adolescence by abdominal pain, bleeding, obstructions or 
intussusceptions (Vasen 2000). Polyps are most commonly reported in the small intestine 
where their occurrence is 80% among PJS patients (Allen et al. 2003). However, polyps are 
found throughout the gastrointestinal tract with occurrences of approximately 40% in 
stomach, colon and rectum (Utsunomiya et al. 1975; Allen et al. 2003) (Fig. 1). In accordance 
with their hamartomatous nature, the PJS polyps are benign and display a pedunculated 
appearance with apparently near-normal cellular composition according to basic histological 
analysis. The most prominent feature is the arborizing smooth muscle core that also serves as 
the defining attribute of a PJS polyp (Fig. 1). 
 
Figure 1. Gastrointestinal polyposis in Peutz-Jeghers syndrome.  
A. Polyps are observed in the stomach and small intestine by gastroscopy. The schematic 
picture on the left points the typical localization of tumors. F, fundus; P, pylorus; D, 
duodenum. B. Normal cellular composition of the gastrointestinal tract contains epithelium 
surrounded by connective tissue of lamina propria and layers of smooth muscle. In a 
histological HE-staining, PJS polyps distinctively display a branching smooth muscle core 
(black arrow) together with lamina propria and non-dysplastic epithelium. Modified from 
Katajisto et al. 2007. 
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As there currently is no noninvasive therapy for PJS polyposis, the management is restricted 
to surgery. Patients are often forced to undergo multiple laparotomies in order to rid 
themselves of symptomatic polyps. Surveillance recommendations propose upper 
gastrointestinal endoscopy and colonoscopy every 2-3 years to facilitate the removal of 
clinically relevant polyps prior to complications (Giardiello et al. 2006; Zbuk et al. 2007). 
Even though the surveillance of polyposis particularly in the small intestine will benefit from 
advances in the capsule and double-balloon endoscopy, development of therapies reducing 
polyp growth is desirable, as they would reduce the need of surgical interventions.  
In addition to gastrointestinal hamartomatous polyps, PJS patients have an increased risk of 
cancer (Giardiello et al. 1987; Spigelman et al. 1989; Gruber et al. 1998; Lim et al. 2004; 
Hearle et al. 2006; Mehenni et al. 2006) with 4-15 fold relative risk of any cancer as 
compared to the general population (Giardiello et al. 2000; Hearle et al. 2006; Mehenni et al. 
2006). While gastrointestinal cancers are most frequent with 90-270 fold relative risk 
(Giardiello et al. 2000; Hearle et al. 2006; Mehenni et al. 2006), increased risk of pancreatic, 
lung, breast, and gynecologic cancers have also been reported (Lim et al. 2004; Hearle et al. 
2006). Whether the coinciding locale of the benign hamartomatous polyps in PJS predisposes 
to the dramatically high incidence of gastrointestinal cancers has remained an open question. 
Dysplasia is occasionally noted in PJS polyps suggesting that such “hamartoma-carcinoma” 
sequence may exist (Bosman 1999). 
 
Genetics of PJS – discovery of LKB1  
Genetic linkage studies demonstrated that inactivating mutations in the serine-threonine 
kinase LKB1 (STK11) are found in PJS (Hemminki et al. 1997; Hemminki et al. 1998; Jenne 
et al. 1998). This distinguished LKB1 as the first identified tumor suppressor kinase. The 
LKB1 gene spans 23kb and has 10 exons. Even though LKB1 mutations are found with 
comparable frequencies in both sporadic and familial PJS cases (Ylikorkala et al. 1999; 
Boardman et al. 2000; Scott et al. 2002), the overall detection frequency of LKB1 inactivating 
mutations has varied between 21-70% in studies relying on analysis of the coding region and 
splice site mutations. (Nakagawa et al. 1998; Wang et al. 1999; Westerman et al. 1999; 
Ylikorkala et al. 1999; Boardman et al. 2000; Olschwang et al. 2001; Scott et al. 2002; Lim et 
al. 2003; Schumacher et al. 2005; Mehenni et al. 2007). Together with reports on PJS 
families unlinked to LKB1 (Mehenni et al. 1997; Olschwang et al. 2001), this relatively low 
rate of detected mutations suggested the possible existence of other PJS loci. However, 
studies on 19q13.4, that demonstrates genetic linkage to some PJS families, have not revealed 
mutations in the subsequently screened genes (Marneros et al. 2001; Buchet-Poyau et al. 
2002; Hearle et al. 2004) and so far other PJS loci have not been identified.  
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LKB1 interacting proteins 
LKB1 is a kinase of 433 amino acids that shares little relation with any particular kinase 
family of the human kinome (Manning et al. 2002). It forms a trimeric complex with a 
pseudokinase STRAD and the scaffolding protein MO25 (Baas et al. 2003; Boudeau et al. 
2003; Brajenovic et al. 2004). There are two functionally redundant isoforms (α and ß) of 
both STRAD and MO25, and the trimeric complex is tethered to the cytoplasm (Baas et al. 
2003; Boudeau et al. 2003). This is where LKB1 also appears to mediate its known cellular 
functions, including the ability to suppress growth (Tiainen et al. 2002). Importantly, 
formation of the trimeric complex is required for full kinase activity of LKB1 (Baas et al. 
2003; Boudeau et al. 2003). Some of the point mutations of LKB1 found in PJS disrupt the 
complex formation in addition to kinase activity (Boudeau et al. 2004), suggesting a role for 
STRAD and MO25 in molecular pathogenesis of PJS.  
Figure 2. LKB1 signaling pathways mediated by the 14 substrate kinases. 
 Following the discovery of AMPK kinase family substrates, LKB1 has been implicated in various 
aspects of cellular metabolism and polarity control. Functions of some LKB1 substrates appear to 
overlap, as is exemplified by repression of CREB mediated transcription via TORC2 
phosphorylation by both SIKs and AMPKs. Whereas SIK1 and SIK2 are inactivated through 
hormonal induction of cAMP and PKA (Katoh et al. 2004; Screaton et al. 2004; Shaw et al. 2005), 
AMPK inactivates TORC2 in response to elevated AMP at least in cultured hepatocytes (Koo et 
al. 2005). Thus this pathway integrates cellular (AMPK) and hormonal (SIK) inputs to negatively 
regulate transcriptional events promoting synthesis of gluconeogenic enzymes (Shaw et al. 2005). 
See text for more detailed introduction to the relevance of the other pathways in PJS. Modified 
from Katajisto et al. 2007. 
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Another LKB1 interactor, BRG1, was identified with LKB1-GST pull down from an in vitro 
translated HeLa cell cDNA library (Marignani et al. 2001). BRG1 is interesting regarding the 
LKB1 tumor suppressor function as Brg1 heterozygous mice form subcutaneous tumors 
(Hendricks et al. 2004), and loss of BRG1 is a prognostic indicator of non-small cell lung 
cancer (Fukuoka et al. 2004); the lung cancer type also associated with loss of LKB1 (see 
below). BRG1 is the essential catalytic helicase of the SWI/SNF chromatin remodeling 
complex, and is involved with epigenetic regulation of gene expression (Xi et al. 2008) 
important in development, differentiation and carcinogenesis. Upon association with BRG1, 
LKB1 has been proposed to stimulate BRG1 and to have a role in BRG1 dependent growth 
arrest (Marignani et al. 2001). 
Facilitated by the increased activity of STRAD:MO25 bound LKB1, the first physiological 
substrate of LKB1 was identified to be the AMP-activated protein kinase (AMPK) (Hawley 
et al. 2003; Woods et al. 2003; Shaw et al. 2004). The number of physiological substrates 
quickly extended to 14 serine/threonine kinases referred to as the AMPK-related kinases or 
AMPK subfamily due to sequence similarity of their kinase domains (Lizcano et al. 2004; 
Jaleel et al. 2005). LKB1 phosphorylates the "T-loop" threonine in the kinase domain of the 
substrates, and this phosphorylation is required for their full activity. Via the substrates, 
LKB1 is implicated to regulate cellular energy management and polarity, and possibly other 
pathways as functions of some substrates are poorly characterized (Fig. 2). 
 
LKB1 regulates cellular energy levels and protein synthesis 
Depletion of cellular ATP is reflected as an increase of free AMP, which leads to activation 
of AMPK (Kahn et al. 2005). For AMPK to be active, the trimeric AMPK complex needs to 
bind AMP in order to allow the activating phosphorylation by LKB1 (Hawley et al. 2003). 
AMPK therefore functions as the cellular energy sensor, and upon activation it shuts down 
lipid and glycogen synthesis and promotes fatty acid oxidation and glycolysis to restore 
cellular energy levels (Fig. 2) (reviewed in Carling 2005). In addition, AMPK also targets 
both transcription (Foretz et al. 1998; Koo et al. 2005) and translation (Bolster et al. 2002) to 
inhibit cell growth and proliferation (Carling 2005). To inhibit translation, AMPK 
phosphorylates and activates TSC2, which suppresses the mTOR pathway activation 
(Corradetti et al. 2004; Shaw et al. 2004). Interestingly, TSC2 is a tumor suppressor mutated 
in tuberous sclerosis (Consortium 1993; van Slegtenhorst et al. 1997) that is characterized by 
various features including hamartomatous tumors in diverse organs (Jozwiak 2006). This 
similarity in etiology between TSC and PJS suggests a possible role for deregulated AMPK-
mTOR pathway in PJS type polyp development.  
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Regulation of polarity by LKB1 
The involvement of LKB1 in polarity control was first noted in C. elegans where two of the 
identified mutants failing in asymmetric cell divisions were the orthologues of mammalian 
LKB1 and MARK kinases (Fig. 2) termed par-4 and par-1 respectively (Kemphues et al. 
1988). Supporting a role for LKB1 also in mammalian polarity control, co-expression of 
LKB1 and STRAD in epithelial cancer cells resulted in a formation of an actin cap and in a 
directed endosomal transportation resembling polarization (Baas et al. 2004). Besides the 
four MARK kinases, the LKB1 substrates BRSK1 and BRSK2 (SAD-A and SAD-B) (Fig. 2) 
have also been implicated in polarity regulation as their double knockout leads to reduced 
axon growth and mislocalization of axon and dendritic markers in mouse (Crump et al. 2001; 
Kishi et al. 2005). This neuronal polarity regulation by BRSKs is dependent on activation by 
LKB1 (Barnes et al. 2007). 
Suggesting that disruption of cellular polarity might also play a role in tumorigenesis 
following LKB1 deletion, LKB1 depletion by RNAi in lung cancer cell lines causes cell 
polarity defects including aberrant Golgi positioning, reduced lamellipodia formation, and 
aberrant morphology (Zhang et al. 2008). Based on the general relevance of polarity in 
tumorigenesis and cancer, it has also been speculated that PJS polyposis may be a result of 
polarity defects of the gastrointestinal epithelium (Jansen et al. 2006; de Leng et al. 2007). 
 
LKB1 in the control of cell proliferation 
Polyp formation in PJS could be due to the increased cell proliferation or decreased apoptosis 
resulting in imbalance of renewal and death of cells. Several studies indicate that re-
introduction of LKB1 into various cancer cell lines lacking its expression induces a G1 cell 
cycle arrest (Tiainen et al. 1999; Sapkota et al. 2001; Shen et al. 2002; Jimenez et al. 2003; 
Qiu et al. 2006), and in some studies the noted G1 arrest correlates with the induction of cell 
cycle regulator p21WAF/CIP (Shen et al. 2002; Tiainen et al. 2002). Moreover, the LKB1 
induced growth arrest is dependent on LKB1 kinase activity as several mutants failed to 
inhibit cell growth (Tiainen et al. 1999).  
The Wnt signaling pathway is intimately involved with gastrointestinal proliferation and 
tumorigenesis (reviewed in Radtke et al. 2006) (see Box 1). LKB1 has been reported to 
suppress Wnt signals by phosphorylation of MARK3/PAR1A to inhibit Wnt mediator 
disheveled (Spicer et al. 2003). In addition, LKB1 has been reported to modulate Wnt-
signaling both positively (Ossipova et al. 2003) and negatively (Lin-Marq et al. 2005) via 
direct regulation of GSK3ß, a kinase targeting ß-catenin for degradation. Consequently, the 
relationship of Lkb1 with the Wnt pathway is unclear.  
Similarly to Wnt signaling, the role of LKB1 in apoptosis is currently ambiguous. Lkb1 has 
been reported to mediate p53-dependent apoptosis by physically interacting with p53 
(Karuman et al. 2001). On the other hand, LKB1 deficient cells are sensitized to apoptosis 
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(Shaw et al. 2004). Furthermore, the LKB1 substrates NUAK1 and NUAK2 (Fig. 2) have 
been linked to apoptosis indirectly (reviewed in Alessi et al. 2006).  
Taken together, several LKB1 mediated signaling pathways with potential implications in 
tumorigenesis been identified. The relevance of these pathways in PJS pathology has 
however not been addressed, and it is unclear whether they or other yet undiscovered 
pathways underlie PJS tumorigenesis.  
 
Mouse model of PJS 
The identification of LKB1 enabled the generation of mice with targeted mutations at the 
Lkb1 locus in an attempt to create a mouse model for PJS, and to study this novel tumor 
suppressor in a physiological setting. Homozygous inactivation of Lkb1 demonstrated that the 
gene is essential for embryogenesis (Ylikorkala et al. 2001; Bardeesy et al. 2002; Jishage et 
al. 2002; Miyoshi et al. 2002). Lkb1-/- mouse embryos do not survive beyond embryonic day 
E10.5, and display severe defects in their vasculature demonstrating a critical function of 
Lkb1 in murine angiogenesis possibly through regulation of vascular endothelial growth 
factor VEGF (Ylikorkala et al. 2001).  
Analysis of heterozygous Lkb1+/- mice confirmed the tumor suppressor function of Lkb1 as 
the heterozygous mice exhibited widespread gastrointestinal polyposis (Bardeesy et al. 2002; 
Jishage et al. 2002; Miyoshi et al. 2002; Rossi et al. 2002). Polyps are detected at 5 months, 
and cause premature lethality by gastrointestinal obstruction from 8 months onwards. 
Importantly, the polyps were remarkably similar to hamartomas of PJS patients both 
macroscopically and histologically, indicating that the Lkb1+/- mouse represents a mouse 
model of PJS (Bardeesy et al. 2002; Jishage et al. 2002; Miyoshi et al. 2002; Rossi et al. 
2002).  
The generation of a PJS mouse model has enabled a more detailed analysis of the molecular 
mechanisms involved in PJS-type polyposis. From the viewpoint of therapy development, the 
two discoveries on the mTOR and COX-2 pathways in the Lkb1+/– mouse polyps are 
particularly interesting. The in vitro discovered LKB1-AMPK-TSC2-mTOR link (see above 
and Fig. 2) implied that increased mTOR activity might participate to tumor development in 
PJS.  Supporting this notion, increase in phosphorylation of mTOR effectors S6K1, S6 and 
4E-BP was noted in the polyps of Lkb1+/– mice (Shaw et al. 2004). These results suggest that 
inhibition of mTOR by rapamycin might suppress polyposis.  
Induction of COX-2 was noticed already by one of the original studies describing the PJS 
mouse model (Rossi et al. 2002). COX enzymes catalyze the rate-limiting step in the 
synthesis of prostaglandins, which are bioactive lipid molecules mediating a large variety of 
tissue-specific effects (reviewed in Cha et al. 2007). While the isoform 1 of COX (COX-1) is 
constitutively expressed and catalyses production of prostaglandin PGI2 (Craven et al. 1983; 
Smith et al. 1982; Lawson et al. 1987) that is important for homeostasis maintenance of 
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gastric mucosal surface (McAdam et al. 1999), COX-2 is inducible by inflammatory stimuli 
and synthesizes most importantly PGE2 (Herschman et al. 1995) (Fig. 3). 
COX-2 induction has also been noted in PJS patient polyps (Rossi et al. 2002; De Leng et al. 
2003; McGarrity et al. 2003; Wei et al. 2003; Takeda et al. 2004) and carcinomas (De Leng 
et al. 2003; Wei et al. 2003). COX-2 is also induced in sporadic intestinal adenomas and 
adenocarcinomas (Eberhart et al. 1994), and in FAP polyps as COX-2 is a downstream target 
of ß-catenin/Tcf-signaling that is activated following APC mutations (reviewed in Wang et al. 
2005) (Fig. 3). Lkb1+/- polyps demonstrate a modest increase of β-catenin, but it is strictly 
localized to the cell membrane of the epithelial cells (Rossi et al. 2002) suggesting that 
deregulated Wnt signaling is not the cause of Cox-2 induction in Lkb1+/- polyps. However, 
pharmacological COX inhibition has been effective in polyp suppression both in FAP 
patients (Giardiello et al. 1993) and in FAP mouse models (Oshima et al. 1996), indicating 
the important role of COX-2 induction in FAP polyposis. This chemopreventive effect in 
FAP together with the noted COX-2 induction in Lkb1+/- polyps suggests that COX-2 may 
also contribute to PJS type polyposis. 
 
 
 
Figure 3. Roles of COX-2 in cancer.  
COX-2 derived PGE2 is a mediator of multiple molecular mechanisms that contribute to 
carcinogenesis. These include inhibition of apoptosis, increase of proliferation and induced 
angiogenesis. Whether mutations of LKB1 cause induction of COX-2 via deregulation of ß-
catenin (as is the case in FAP due to APC mutations), or via another yet unidentified pathway 
is unclear. Modified from Wang et al. 2005. 
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Loss of heterozygosity of LKB1 and polyp development 
According to the classical tumor suppressor definition both alleles of the tumor suppressor 
gene must be inactivated for oncogenic effects to take place. According to this dogma, loss of 
heterozygosity (LOH) of the tumor suppressor gene marks the cells driving familial 
tumorigenesis. Surprisingly, subset of the murine hamartomatous polyps have a functional 
copy of Lkb1 in both epithelial and stromal cells (Jishage et al. 2002; Miyoshi et al. 2002; 
Rossi et al. 2002), suggesting that haploinsufficiency of Lkb1 may be sufficient for polyp 
formation. This is consistent with the observation of protein levels and kinase activity being 
similarly decreased in both normal heterozygote tissues as well as in polyps (Miyoshi et al. 
2002; Rossi et al. 2002).  
Interestingly, a study on human PJS polyps utilizing fluorescent resonance energy transfer 
demonstrated the presence of the wild-type LKB1 allele also in hamartomatous PJS polyps 
(Hernan et al. 2004). More recently, it has even been proposed that PJS polyps in fact are 
simple mucosal prolapses resulting from asymmetrical stem cell division induced by Lkb1 
haploinsufficiency, and omitting requirement of a “second hit” (Jansen et al. 2006; de Leng et 
al. 2007). On the other hand, previous analyses of human PJS polyps found evidence for 
LOH of LKB1 in many of the analyzed polyps (Gruber et al. 1998; Hemminki et al. 1998; 
Miyaki et al. 2000; Entius et al. 2001), and evidence for Lkb1 inactivation in some of the 
mouse tumors has also been reported (Bardeesy et al.). Consequently, the requirement of 
LKB1/Lkb1 LOH for PJS-type polyp development is unclear. 
 
LKB1 and cancer in PJS 
The increased risk of multiple cancer types in PJS patients suggests that inactivation of LKB1 
promotes cancer. In studies comparing the frequency of LKB1 LOH in polyps and 
carcinomas of PJS patients, LOH has been detected in average in 41% of polyps and in 85% 
of carcinomas demonstrating a 2.2-fold higher incidence of LKB1 LOH in carcinomas (Wang 
et al. 1999; Miyaki et al. 2000; Entius et al. 2001; De Leng et al. 2003). Moreover, several 
studies on PJS related cancers including liver, colorectal, breast, pancreas and sex cord 
tumors report the biallelic loss of LKB1 (Connolly et al. 2000; Entius et al. 2001; Sato et al. 
2001; Kim et al. 2004; Nakanishi et al. 2004).  
Many of the studies using various Lkb1+/- mice have not observed increased cancer incidence, 
but this may be due to the relatively early age (8-12 months) at which the majority of mice 
develop fatal large hamartomas occluding the gastrointestinal tract. Attempts to accelerate the 
development of carcinomas have been made using mice with loss of the p53 tumor 
suppressor, but while hamartomas in these mice develop somewhat earlier (Takeda et al. 
2005; Wei et al. 2005), the tumors do not display signs of progression nor LOH of Lkb1.  
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Supporting the notion that malignancies do not have time to develop in Lkb1+/- mice, analysis 
of aged Lkb1+/- mice specimen that did not succumb to occlusions from large polyps revealed 
that over 70% of Lkb1+/- mice that survived until 50 weeks of age had hepatocellular 
carcinomas (HCC) (Nakau et al. 2002). All analyzed HCCs demonstrated Lkb1 LOH, never 
noted in the hamartomas in this same line of mice (Miyoshi et al. 2002; Nakau et al. 2002). 
Recently another study demonstrated that also spontaneous endometrial adenocarcinomas 
develop with long latency in Lkb1+/– mice and demonstrate Lkb1 LOH (Contreras et al. 
2008). In summary, accumulating data from PJS and the Lkb1+/– mouse model support the 
notion that biallelic LKB1 deletion can promote cancer.  
 
LKB1 and sporadic cancer 
Despite the link of LKB1 with malignancies in PJS patients, LKB1 mutations appear to be 
uncommon in most sporadic cancers (Resta et al. 1998; Connolly et al. 2000; Sobottka et al. 
2000; Trojan et al. 2000; Sato et al. 2001; Forbes et al. 2006). A notable exception is that up 
to 34% of primary lung adenocarcinomas and 27% of lung squamous cell carcinomas harbor 
somatic LKB1 gene mutations (Sanchez-Cespedes et al. 2002; Conde et al. 2007; Ji et al. 
2007; Matsumoto et al. 2007). An even higher portion of Lkb1 mutations was discovered in 
cell lines derived from lung adenocarcinomas with frequencies of 54-42% (Carretero et al. 
2004; Ikediobi et al. 2006; Matsumoto et al. 2007). Taken together, the above studies warrant 
further attention towards LKB1 with close to 20 000 deaths yearly in the US alone from lung 
cancers harboring (at least) LKB1 loss presuming a 25% frequency of LKB1 loss in just lung 
adenocarcinomas (http://www.cdc.gov/cancer/lung/statistics/). 
Interestingly the human lung adenocarcinomas with LKB1 mutations also carry Ras 
mutations significantly more often than expected by random (Matsumoto et al. 2007). 
Paradoxically, evidence for genetic interaction between Ras and Lkb1 first came from 
transformation assays demonstrating that Lkb1–/– MEFs were in fact resistant to Ras induced 
transformation (Bardeesy et al. 2002). However, conditional activation of Ras and deletion of 
Lkb1 in the mouse lung demonstrated that Lkb1 loss cooperates with Kras in driving lung 
cancer (Ji et al. 2007). In this setting, deletion of Lkb1 increased both cancer initiation and 
metastasis, and showed the strongest Kras cooperation of the assayed tumor suppressors, 
including p53. Underlining the tissue specific relationship of LKB1 and RAS activation, RAS 
mutations in the PJS polyps are rare (Entius et al. 1997). 
Conditional targeting of mouse Lkb1 also enabled studies on biallelic Lkb1 loss in other 
tissues than the lung. Biallelic Lkb1 deletion induced by adenoviral-Cre in the endometrial 
epithelium caused adenocarcinomas mimicking the spontaneously developing cancers in 
Lkb1+/– mice (Contreras et al. 2008). Similarly, epidermal (K14-Cre) loss of Lkb1 caused 
squamous cell carcinomas of the skin in a subset of mice with long latency, and sensitized 
mice significantly to carcinogen-induced tumorigenesis (Gurumurthy et al. 2008). In a third 
study targeting epithelial cells the biallelic loss of Lkb1 in the pancreatic epithelium resulted 
Review of the Literature 
 21 
in polarity defects and pancreatic serous cystadenomas (Hezel et al. 2008). Contrasting the 
epithelial Lkb1 deletions, loss of Lkb1 in skeletal muscle or cardiac muscle did not lead to 
cancer (Sakamoto et al. 2005; Sakamoto et al. 2005). In addition to supporting the association 
of epithelial Lkb1 loss and carcinogenesis, these results demonstrate the tissue dependent 
response to Lkb1 deficiency. The results are also interesting considering the complex 
histology of the PJS polyps that contain both gastrointestinal epithelial cells and smooth 
muscle cells. The effect of Lkb1 loss in these cell types has not yet been addressed. 
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AIMS OF THE STUDY 
LKB1 has been implicated in the molecular pathogenesis of PJS and sporadic cancer. This 
study was undertaken to investigate the mechanism of LKB1 tumor suppression in PJS 
polyposis.  
In order to understand the molecular pathogenesis underlying PJS, the first aim of the study 
was to investigate the possibility of mutations in loci other than LKB1. Identification of such 
a second PJS gene could also enlighten how LKB1 mediates its tumor suppressor function. 
Based on the observation of increased COX-2 expression in the PJS polyps the second aim 
was to investigate the therapeutic potential of COX-2 inhibition in PJS in order to understand 
the relevance of COX-2 induction in PJS and to develop the first PJS therapy strategy.  
PJS polyps are distinctive in their histology and contain a notable amount of stromal cells. 
Together with the possibility that LKB1 is haploinsufficient regarding its tumor suppressor 
function, this raises the possibility of non-epithelial origin of tumorigenesis. By deleting Lkb1 
tissue specifically in the smooth muscle, the third aim of this study was to explore the 
function of stromal Lkb1 and the role of the smooth muscle component in the PJS polyp 
development. 
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RESULTS AND DISCUSSION 
No evidence for PJS loci besides LKB1 (I) 
Apart from LKB1, the studies on chromosomal regions that exhibit genetic linkage with PJS 
have not revealed mutations in the screened candidate genes (Marneros et al. 2001; Buchet-
Poyau et al. 2002; Hearle et al. 2004). To understand the full genetic background of PJS, 
patients that did not harbor identified mutations of LKB1 were screened for mutations in the 
functionally related LKB1 interactors STRAD and MO25, and LKB1 interactor BRG1.  
STRADα and MO25α did not harbor any mutations in the coding regions, and the 
polymorphisms noted in the non-coding regions were in silico predicted not to affect splicing. 
Supporting this result, another study undertaken during the course of this thesis work 
demonstrated that in addition to STRADα investigated here, also STRADß is void of 
mutations in PJS patients (de Leng et al. 2005).  These results support the notion that 
mutations in LKB1 binding partners STRAD and MO25 do not cause PJS.  
Only one novel silent mutation (Pro372Pro, 980A>C) in the coding region of BRG1 of one 
patient was found to discern the PJS patients from healthy subjects. Even though this 
mutation was predicted to alter acceptor splice site in silico, RT-PCR analysis did not reveal 
any alternate transcripts. Thus no evidence was found for mutations of BRG1 participating in 
the molecular pathogenesis of PJS.  
During the progress of this work, also the four MARK kinases have been investigated and 
were found not to harbor mutations in the PJS patients without identified mutations in LKB1 
(de Leng et al. 2007). On the other hand, frequency of LKB1 mutations in PJS has been 
further defined to account for 68-94% of the PJS cases (Table 1) as the use of multiplex 
ligation-dependent probe amplification (MLPA) has enabled the identification of large 
deletions that are undetectable with classic sequencing strategies. Demonstrating the 
significance of previously undetected LKB1 deletions, a study noting mutation frequency of 
52% in LKB1 by sequencing, detected 94% mutation frequency with the additional use of 
MLPA (Aretz et al. 2005). The average LKB1 mutation frequency of 81% in the 241 PJS 
families currently analyzed with MLPA, demonstrates that technical inadequacies in the 
earlier reports account for the lower reported (52% average) frequencies. Furthermore, even 
higher frequency of LKB1 mutations is probable considering the possibility of intronic 
mutations and yet unscreened deletions. Together with lack of evidence for a “second PJS 
gene” this suggests that over 94% of all PJS cases harbor LKB1 inactivating alterations. 
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  Reference mut/all Frequency 
Sequencing   
 (Nakagawa et al. 1998) 10/15 67% 
 (Wang et al. 1999) 7/12 58% 
 (Westerman et al. 1999) 12/19 63% 
 (Ylikorkala et al. 1999) 19/33 58% 
 (Jiang et al. 1999) 1/10 10% 
 (Boardman et al. 2000) 6/28 21% 
 (Olschwang et al. 2001) 24/34 70% 
 (Scott et al. 2002) 6/14 46% 
 (Lim et al. 2003) 17/33 52% 
 (Schumacher et al. 2005) 27/41 66% 
 (Mehenni et al. 2007) 27/46 59% 
MLPA   
 (Aretz et al. 2005) 67/71 94% 
 (Chow et al. 2006) 24/33 73% 
 (Volikos et al. 2006) 59/76 80% 
 (Hearle et al. 2006) 25/38 68% 
 (de Leng et al. 2007) 21/23 91% 
 
 
To directly investigate on LKB1 activity in PJS patients that have been screened by both 
sequencing (Ylikorkala et al. 1999) and MLPA (Volikos et al. 2006) but have not been 
identified to carry LKB1 mutations, a lymphoblast cell line derived from such patient was 
analyzed by LKB1 kinase assay. In this assay LKB1 was immunoprecipitated and 
subsequently the kinase activity of the precipitate was quantified. Interestingly, this method 
demonstrated reduced LKB1 activity in all of the assayed (n=3) PJS patient cell lines 
including the one without an identified LKB1 mutation (Fig. 4, unpublished). This result 
supports the notion that LKB1 underlies most if not all PJS cases, and suggests that the 
patients without identified LKB1 mutations may for example harbor heritable epigenetic 
changes of LKB1 similarly to what has been noted in models of other tumorigenesis 
predisposing conditions (Linhart et al. 2007). Furthermore, the used kinase assay might 
provide means for LKB1 activity based PJS diagnosis, but further studies with larger material 
are needed to validate the robustness of the assay.  
 
Table 1. Detected frequencies of LKB1 mutations in PJS. 
For each study the number of families with detected mutations and the number of 
all analyzed families (mut/all) are shown. The frequency of LKB1 mutations in 
PJS is calculated accordingly for each report (Frequency). Studies using 
conventional sequencing based methods or MLPA are presented separately, as the 
reports using the latter are likely to represent more accurate estimates (see text) 
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Figure 4. Detection of reduced LKB1 kinase activity in 
lymphoblast cell lines from PJS patients.  
In comparison to control samples (green), PJS samples 
with and without identified LKB1 mutations (red and 
black respectively) exhibit lower LKB1 kinase activity.  
All measurements are normalized according to CDK7 
kinase activities of the cell lines.  
 
 
COX-2 expression is an early, but not required event in Lkb1+/– polyp 
development (II) 
While multiple reports have demonstrated COX-2 expression of polyps from Lkb1+/– mice 
and PJS patients (Rossi et al. 2002; De Leng et al. 2003; McGarrity et al. 2003; Wei et al. 
2003; Takeda et al. 2004), it has not been addressed whether COX-2 expression represents a 
late feature of PJS type polyps or an early event possibly contributing to the polyp initiation. 
To address this, a panel of polyps ranging in diameter from the smallest polyps 
distinguishable in a nonfixed mouse stomach to polyps commonly found in terminal animals 
was collected from Lkb1+/– mice, and analyzed for COX-2 protein levels. All polyp size 
categories (1mm, 2mm, 5mm) demonstrated induced COX-2 in a subset (43%, 57%, 63% 
respectively) of polyps. The observation of high COX-2 already in the smaller polyps 
indicates that COX-2 induction is a common early event in development of PJS type 
hamartomatous polyps, and possibly has an impact on further polyp development. However, 
in concordance with previous studies (Rossi et al. 2002; Takeda et al. 2004) the lack of COX-
2 in a subset of polyps demonstrates that COX-2 is not required for polyp initiation and 
development. Furthermore, studies on other hamartomatous polyps with mutations in the 
Smad4, Cdx2 or BMPR1 have demonstrated that COX-2 induction is a common event 
occurring with hamartoma growth (Takeda et al. 2004; Kurland et al. 2007). 
 
Genetic inactivation of Cox-2 reduces polyp burden (II) 
To study the relevance of COX-2 in Lkb1+/– polyposis, mice heterozygous for Lkb1 and 
hetero- or homozygous for inactivating allele of the Cox-2 gene were generated. Whereas the 
number of small polyps was similar in Lkb1+/–;Cox-2+/– and Lkb1+/–;Cox-2–/– mice as 
compared to Lkb1+/– mice at 8,5 months of age, the number of large polyps was significantly 
reduced in both Lkb1+/–;Cox-2+/– and Lkb1+/–;Cox-2–/– mice. This reduction in number of 
large polyps was reflected as a significant reduction also in total polyp burden of Lkb1+/–
;Cox-2+/– and Lkb1+/–;Cox-2–/– mice demonstrating a significant role for COX-2 expression 
in pathogenesis of PJS-type polyposis in Lkb1+/– mice. 
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Pharmaceutical COX-2 inhibition by celecoxib hinders tumor growth (II) 
The noted efficacy of genetic COX-2 ablation suggested that also pharmacologic intervention 
of COX-2 could reduce polyposis. As COX-2 is a target of multiple drugs including widely 
used NSAIDs such as aspirin and ibuprofen, pharmacologic inhibition of COX-2 activity is 
possible with simple oral administration of approved drugs. However, the aforementioned 
drugs also inhibit activity of COX-1 and cause adverse effects such as dyspepsia and peptic 
ulceration in the gastrointestinal tract (reviewed in Lanas et al. 2006). The newer COX-2 
inhibitors selectively inhibit COX-2 while the mucosa protective function of COX-1 is 
maintained. Therefore the polyp growth-reducing efficacy of COX-2 inhibition was studied 
with a selective COX-2 inhibitor celecoxib in two cohorts of Lkb1+/– mice with treatments 
starting either before (3,5 months) or after (6,5 months) polyposis onset. In comparison to 
untreated Lkb1+/– mice, Lkb1+/– mice that had received 1500 ppm of celecoxib from age of 
3,5 months until analysis at 10 months demonstrated 86% reduction (P < 0,001) in polyp 
burden. Polyp burden was, as with the genetic intervention, reduced due to decrease in 
number of large polyps, particularly due to the total lack of polyps > 5mm in diameter 
whereas polyp quantity of the smallest size category was unaffected. Similarly, the cohort 
treated for a shorter 3,5 month period starting after polyposis onset had significantly fewer 
large polyps (47% reduction, P < 0,05) while again the number of small polyps was not 
changed. In the APCmin mouse, celecoxib reduced tumor burden to similar extent (85% 
reduction), but it also reduced the tumor multiplicity of all tumor sizes by up to 70% (Jacoby 
et al. 2000) suggesting a more direct role for COX-2 in development of FAP polyps. Taken 
together, the results suggest that inhibition of COX-2 suppresses Lkb1+/– tumor growth 
without an influence on polyp initiation, and demonstrate that pharmacologic intervention 
with celecoxib effectively reduces polyp burden in the mouse model of PJS. 
 
COX-2 inhibition results in decreased vascularity of Lkb1+/– polyps (II) 
Suggested mechanisms for tumor prevention by COX-2 inhibition include effects on cell 
proliferation, apoptosis, and angiogenesis (Cha et al. 2007). Apoptotic index of Lkb1+/– 
polyps was unaltered in the celecoxib treated mice, likewise to histological appearance 
indicative of unchanged proliferation. In contrast, the microvessel density (MVD) of 
celecoxib treated tumors was reduced by 54% (P<0.01) in comparison to untreated polyps of 
the same size category. These results suggest that COX-2 induces angiogenesis in Lkb1+/– 
mice possibly via up-regulated VEGF and FGF as is noted in FAP (Seno et al. 2002). 
Furthermore, the results suggest that reduced angiogenesis by COX-2 inhibition may be the 
polyp growth suppressing mechanism of celecoxib in Lkb1+/– mice. 
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Celecoxib reduces polyposis severity in PJS patients (II) 
The elevated COX-2 in PJS patient polyps (Rossi et al. 2002) together with the encouraging 
results from the PJS mouse model prompted an investigation on therapeutic potential of 
COX-2 inhibition in PJS. In a pilot clinical trial, 8 PJS patients received 2 x 200mg of 
celecoxib daily for 6 months. Video recorded gastroscopies before and after celecoxib were 
used to address polyposis grade in the stomach and duodenum, and revealed gastric polyps in 
all subjects. The multitude of observed gastric polyps (II, figure 4) suggests that previous 
reports on low incidence of gastric polyps compared to small intestine (Allen et al. 2003) 
may simply reflect a higher incidence of symptoms due to intestinal polyps rather than polyp 
distribution. Polyposis severity was significantly reduced after celecoxib in 2 out of the 6 
patients with gastroscopy recordings allowing grading. The overall grade of polyposis of all 6 
patients was also reduced (P<0.01), and it is interesting to note that the most dramatic effect 
was observed in the patient with the highest polyp burden prior to treatment. Despite the 
short treatment period, these results demonstrate the efficacy of pharmaceutical COX-2 
inhibition by celecoxib in PJS polyposis suppression in at least a subset of patients. However, 
selective COX-2 inhibitors have been associated with cardiovascular events in long-term 
follow-ups undertaken during this thesis work (Graham et al. 2005). The balance of benefits 
to risk for celecoxib chemoprevention in general population with normal risk of 
gastrointestinal tumors has therefore been regarded unfavorable (Rostom et al. 2007). 
Whether the benefits of selective COX-2 inhibition for PJS patients with their high 
occurrence of gastrointestinal tumors warrants COX-2 chemoprevention, calls for larger 
clinical trials to fully establish the therapeutic efficacy of COX-2 inhibition in this disease. 
 
Deletion of Lkb1 in smooth muscle cells (III) 
Influenced by the well-defined mechanism of colorectal carcinogenesis starting from 
epithelial mutations of the APC tumor suppressor (reviewed in Fodde et al. 2001), 
gastrointestinal tumorigenesis in general has been considered to follow similar epithelially 
originating path. Contrasting APC mutations in FAP, studies on LKB1/Lkb1 deletions in PJS-
type polyps have not elucidated the tissue type(s) critical for polyp development, as data on 
LOH of LKB1/Lkb1 has been ambiguous. To investigate whether smooth muscle cells 
(SMCs) that form the distinctive stromal “core” of PJS polyps actively contribute to polyp 
development, Lkb1 was deleted tissue specifically in mouse SMCs by the use of conditional 
Lkb1lox allele (Bardeesy et al. 2002) and a SM-CreERT2(ki) allele (Kuhbandner et al. 2000) 
expressing tamoxifen inducible Cre-recombinase under the SM22/Transgelin (Tagln) 
promoter in SMCs. The SM-CreERT2(ki) allele is here forth referred to as TaglnCre  
according to the official gene symbol. 
The specificity of Lkb1 deletion was assessed with LCM-PCR from mice at 3 months (1,5 
months after the recombination induced by the tamoxifen injections) demonstrating the 
recombined Lkb1– allele only in samples containing smooth muscle cells. The 50% efficiency 
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of Lkb1 recombination noted in SMCs at 8 months indicates that either the recombined SMCs 
are sustained for at least 6,5 months or that the used strategy targets a SMC progenitor cell. 
The latter option is unlikely as SM22/Tagln expression is a marker of myogenic 
differentiation (Chen et al. 2006).  
 
Lkb1 heterozygosity of the smooth muscle predisposes to polyposis (III) 
Mesenchymally targeted Lkb1lox/+;TaglnCre/+mice exhibited signs of gastrointestinal 
obstruction and premature lethality from 11 months onwards. As expected, also the Lkb1+/- 
heterozygous mice showed similar symptoms, but with shorter latency. In necropsy, terminal 
Lkb1lox/+;TaglnCre/+ animals exhibited widespread gastric polyposis comparable to Lkb1+/– 
mice. Strikingly, the polyps in Lkb1lox/+;TaglnCre/+mice were histologically indistinguishable 
from Lkb1+/- polyps notwithstanding their smaller average size. The noted size difference 
may either reflect the later (6 weeks postnatal) and partial recombination of Lkb1 in smooth 
muscle cells, or slower development of purely stroma-driven polyps. Taken together, these 
results demonstrate that monoallelic inactivation of Lkb1 in SMCs predisposes to polyposis 
and phenocopies the Lkb1+/– mouse model of PJS.  
 
LOH of Lkb1 is not required for polyp development (III) 
Embryonic lethality of biallelic Lkb1 inactivation (Ylikorkala et al. 2001) has previously 
prevented direct investigations on causality of Lkb1 LOH in polyp development. The use of 
the conditional strategy to delete Lkb1 facilitated analysis of animals with Lkb1 nullizygous 
cells. Biallelic deletion of Lkb1 did not appear to influence the short-term viability of smooth 
muscle cells. This was demonstrated by the normal histology of the Lkb1lox/lox;TaglnCre/+ 
gastrointestinal tract that exhibited the recombined Lkb1– allele as determined by PCR 
genotyping 6 weeks after tamoxifen induced deletion. Consistent with this result, mice with 
Lkb1 knockout skeletal or cardiac muscle cells are viable but targeted cells are deficient in 
AMPK activation following contraction or ischemia (Sakamoto et al. 2005; Sakamoto et al. 
2005). Furthermore, the mice with biallelic Lkb1 deletion in the smooth muscle did not 
exhibit compromised survival during the 11-month follow-up.  
When sacrificed at 11 months of age the Lkb1lox/lox;TaglnCre/+ mice exhibited gastrointestinal 
polyposis similar to Lkb1lox/+;TaglnCre/+. The polyps and unaffected GI-tract were 
histologically indistinguishable between the genotypes indicating that biallelic deletion of 
Lkb1 does not cause  progression of polyps or spontaneous cancer. This result is consistent 
with the results from other studies on mesenchymally targeted Lkb1 mutations (Sakamoto et 
al. 2005; Sakamoto et al. 2005), and highlights the different responses to Lkb1 loss in the 
mesenchyme and the epithelium where biallelic deletion has resulted in carcinogenesis 
(Contreras et al. 2008; Gurumurthy et al. 2008; Hezel et al. 2008).  
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Importantly, the size, quantity, and penetrance of the polyps were only moderately higher in 
the biallelic deletion (Fig. 5). This small difference in polyposis severity is in strong 
disagreement with the requirement of Lkb1 LOH for polyp development. Otherwise the noted 
1.8-fold increase in polyp number (unpublished) with biallelic deletion would require more 
than half of the cells in monoallelic deletion to undergo stochastic somatic mutations. This 
finding is also consistent with identification of both monoallelic and biallelic inactivation in 
polyps in both mice (Bardeesy et al. 2002) and Peutz-Jeghers patients (Entius et al. 2001). 
However, whereas mesenchymal deletion of Lkb1 in the gastrointestinal tract causes benign 
hamartomatous polyps, the development of cancer after epithelial Lkb1 deletions in other 
tissues (Contreras et al. 2008; Gurumurthy et al. 2008; Hezel et al. 2008) insinuates that the 
malignant GI-tract cancers in PJS may require epithelial LKB1 loss, and possibly represent a 
different entity to PJS polyps. This issue waits for studies addressing the phenotypes of 
mono- and biallelic deletions of Lkb1 in the gastrointestinal epithelium. 
 
 
 
Epithelial deregulation of mTOR signaling is not the primary defect 
causing PJS polyps (III) 
The discovery of the LKB1-AMPK-TSC2-mTOR signaling link (Corradetti et al. 2004) (see 
Figure 2) and activation of mTOR effectors in Lkb1+/– polyps (Shaw et al. 2004) has led to a 
proposal that LKB1 functions as a tumor suppressor via TSC2 mediated mTOR inhibition. 
Involvement of this pathway in the identified smooth muscle driven tumorigenesis was 
addressed by immunohistochemistry. Surprisingly, mTOR effector ribosomal S6 protein was 
similarly activated in the epithelium of both Lkb1lox/+;TaglnCre/+ and Lkb1lox+/– polyps, 
indicating that mTOR activation at least in the Lkb1lox/+;TaglnCre/+ polyp epithelium is a 
secondary event in polyp development as the epithelium in these polyps does not harbor Lkb1 
mutations.  
Though the mechanism how mesenchymal Lkb1 deletions lead to epithelial mTOR activation 
is unresolved, the results from Lkb1lox/+;TaglnCre/+ mice oppose the proposal of mTOR 
Figure 5. Number of gastric polyps in 11-
month-old mice with mono- and biallelic 
deletions of Lkb1 in the smooth muscle. Each 
circle represents an experimental animal. 
Number of analyzed mice (n), and average 
number of macroscopically detectable polyps 
(black bars, average +/- s.d.) is presented. 
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activation via compromised LKB1-AMPK-TSC2 signaling as the primary cause of PJS 
polyposis. Suggesting that mTOR activation in Lkb1+/– polyps might occur via different 
pathways, cell lines derived from Lkb1–/– squamous cell carcinomas exhibit Lkb1 dependent 
growth arrest that is not abrogated by introduction of dominant negative AMPK despite the 
noted increase in mTOR pathway activity (Gurumurthy et al. 2008). Indirect support for this 
notion also comes from Tsc1+/- and Tsc2+/- mice that do not develop hamartomas in the 
gastrointestinal tract (Kobayashi et al. 1999; Onda et al. 1999; Kobayashi et al. 2001; 
Kwiatkowski et al. 2002). However, inhibition of mTOR with rapamycin was recently 
reported to suppress polyp burden of Lkb1+/– mice by reducing the number of large (>8mm) 
polyps (Wei et al. 2008). The noted effect of rapamycin particularly on large polyps is 
reminiscent of the effect noted with COX-2 inhibition in this thesis. This suggests that 
similarly to celecoxib, also rapamycin treatment might target processes that are important for 
polyp growth, but secondary to tumor initiation caused by Lkb1 deficiency.  
 
Reduced mesenchymal TGFß signaling may cause PJS polyp 
development (III) 
The comparable composition of stroma and epithelium in both Lkb1lox/+;TaglnCre/+ and 
Lkb1+/– polyps suggested that similar mesenchymal response to Lkb1 heterozygosity might 
underlie epithelial proliferation and tumorigenesis in both genotypes. Indeed, the 
immunohistochemical analysis of the myogenic stromal cells revealed altered ratio of 
myofibroblasts (SMA+, desmin–) and SMCs (SMA+, desmin+) to favor myofibroblasts in 
both polyp types compared to normal gastric tissue. LCM-PCR detected the recombined Lkb1 
allele exclusively from SMA+ stromal cells indicating that the myofibroblasts arise due to 
Lkb1 deficiency and designate Lkb1 deletions in Lkb1lox/+;TaglnCre/+ polyps. 
Correspondingly, the SMA– cells located distally to myofibroblasts were negative for Lkb1 
deletions. The propensity of myofibroblasts to express COX-2 (Mifflin et al. 2002) could also 
promote PJS polyp development. However, while COX-2 inhibition reduced average polyp 
size, it had no effect on the number of small polyps in the study II indicating that COX-2 is 
not the alteration of cellular microenvironment that underlies tumor initiation. 
The noted alteration in myofibroblast:SMC-ratio indicated a disturbance in the myogenic 
differentiation normally involving TGFß signaling (Hirschi et al. 1998). Activity of TGFß 
signaling was therefore addressed by analysis of Smad2 signal transducer phosphorylation (p-
Smad2). Stromal p-Smad2 was specifically reduced in the SMA+ cells suggesting that Lkb1 
deficiency results in reduced TGFß signaling. This was confirmed with primary cultures of 
mouse embryonic fibroblasts demonstrating that Lkb1 deletion leads to decrease in TGFß 
production. Furthermore, reduction in TGFß production correlated with the allelic dosage of 
Lkb1, and demonstrated the haploinsufficiency of Lkb1 in this regard. 
For mesenchymal Lkb1 deletion to evoke a tumorigenic response in the epithelium, the 
interaction between the two tissue types must be altered. The noted reduction in 
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mesenchymally produced TGFß is interesting in this setting, as in addition to myogenic 
differentiation TGFß signaling controls epithelial proliferation (Kurokowa et al. 1987; 
Russell et al. 1988).  Importantly, reduction in Smad2 activation was noted also in the 
epithelial cells adjacent to the SMA+ stroma. Furthermore, epithelial proliferation marked by 
Ki-67 positive nuclei coincided with the reduced p-Smad2 suggesting that reduced TGFß 
signaling from the Lkb1 heterozygote mesenchyme results in epithelial proliferation and may 
underlie polyp development (Fig. 6).  
In order to obtain evidence for possible defects in mesenchymal-epithelial TGFß signaling in 
the human disease, Peutz-Jeghers patient polyps were also stained for SMA and p-SMAD2. 
SMA+ cells constituted most of the PJS polyp stroma, but SMA– stromal cells were noted 
distally to SMA+ core of the polyps. Strikingly, the SMA+ stroma and the adjacent epithelial 
cells exhibited reduced p-SMAD2 in comparison to areas with SMA– stroma. Considering 
the results from the Lkb1lox/+;TaglnCre/+ mouse, these results support the role of stroma as a 
major contributor to PJS polyposis by generation of a permissive microenvironment for 
epithelial expansion. 
 
 
 
 
 
 
Landscaper tumor suppressor function of LKB1 (III) 
The surprising results regarding Lkb1 haploinsufficiency and mesenchymal functions make 
Lkb1 hard to categorize as a tumor suppressor. According to the original proposal by Kinzler 
and Vogelstein, tumor suppressors represent two principal modes of action termed as 
gatekeepers and caretakers (Kinzler et al. 1997). Of the two, gatekeepers have maybe the 
more intuitive function, as they directly inhibit tumor cell proliferation or promote cell death. 
Figure 6. Proposed model of PJS-type polyp development. In Lkb1+/+ tissues, mesenchymally 
produced TGFß (pink) drives myogenic differentiation toward mature smooth muscle cells 
(red arrows) and inhibits epithelial proliferation (black line). In the Lkb1lox/+;TaglnCre/+ mouse 
model of PJS smooth muscle specific deletion results in reduced mesenchymal TGFß 
production. This is reflected in the balance of myogenic differentiation to possibly favor 
dedifferentiation of smooth muscle cells, and in impaired mesenchyme-to-epithelium 
signaling. As a result, the number of myofibroblasts increases and leads to further reduction of 
mesenchymal TGFß and in hyperproliferation of the epithelium and polyp development. 
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With examples like Rb, APC and P53 gatekeepers are well appreciated for their importance 
in cancer biology.  
Coinciding with the cancer-promoting propensity of mutations the second group of tumor 
suppressors, the caretakers, function indirectly by maintaining the genomic integrity and 
consequently their loss promotes genomic instability that eventually results either in 
oncogene activation or inactivation of gatekeepers. ATM and ATR, the master controllers of 
DNA damage response, are prototypic caretakers.  
Intrinsic to the definition of gatekeepers and caretakers, their mutations increase the 
oncogenic potential of the mutated cell itself (Kinzler et al. 1998). However, smooth muscle 
specific deletion of Lkb1 caused tumorigenic growth of epithelial cells in addition to the 
targeted mesenchyme. The sufficiency of the two tumor suppressor classes was similarly 
challenged by the discovery of clonally expanded stroma in Juvenile polyposis (JP) polyps 
(Jacoby et al. 1997). Stroma of JP polyps exhibited LOH of the SMAD4 gene, whereas no 
LOH was found in the predominant epithelial cells of the polyps (Howe et al. 1998). This led 
Kinzler and Vogelstein to propose the existence of a third type of tumor suppressor, the 
landscaper (Kinzler et al. 1998). Mutations of a landscaper were proposed to alter the cellular 
microenvironment thereby influencing neighboring cells and inducing, or at least supporting 
their oncogenic potential. However, the molecular mechanism of tumorigenesis driven by 
stromal SMAD4 loss was not characterized, and epithelial cells of JP polyps were later 
demonstrated do harbor SMAD4 mutations (Woodford-Richens et al. 2000). Consequently, 
the whole existence of landscapers was questioned (Playford 2001).  
SMAD4 is an intracellular signal transducer of TGFß signaling; a pathway that the results of 
this study suggest to mediate mesenchymal Lkb1 tumor suppression. Recent investigation on 
murine Smad4 demonstrated that in fact also Smad4 is haploinsufficient in tumor suppression 
of mouse polyps (Alberici et al. 2006) possibly explaining the previous contradictory reports 
on SMAD4 LOH (Howe et al. 1998; Woodford-Richens et al. 2000). It is interesting to note 
that including the results of this study, current evidence supporting the landscaper hypothesis 
comes from mouse models with defects in TGFß superfamily signaling from mesenchyme to 
epithelia. More specifically, deletion of mouse TGFßRII in fibroblasts leads to gastric 
squamous cell carcinoma (Bhowmick et al. 2004), and tissue specific deletion of murine 
Smad4 in T-cells results in gastrointestinal cancer (Kim et al. 2006). Furthermore, blocking 
of stromal BMP4 signals with transgenic expression of noggin in epithelial cells leads to 
adenoma-like lesions (Haramis et al. 2004). In these studies, several deregulated cytokines 
and growth factors (HGF, FGF, IL-6) were implicated in aberrant signaling with the 
epithelium. None of them were altered in Lkb1lox/+;TaglnCre/+ mice, indicating that even 
though deregulated TGFß superfamily signaling may link all these models demonstrating 
mesenchymal induction of epithelial tumorigenesis, specific mechanisms probably vary.  
The observation of Lkb1 haploinsufficiency in TGFß regulation is important, as it provides a 
rational for polyp development without Lkb1 LOH and for infrequency of sporadic PJS type 
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polyps (Burkart et al. 2007). As Lkb1 deletions cause a reduction in mesenchymally produced 
TGFß, the effect of a sporadic LKB1 mutation in a single cell is likely to result only in a 
minute alteration of the cellular microenvironment. Hereditary Lkb1 mutations on the other 
hand reduce TGFß production of all mesenchymal cells lining the whole gastrointestinal 
epithelium, and thus profoundly modulate mesenchymal signaling that normally keeps 
epithelial proliferation at bay (Halttunen et al. 1996). In addition, the effect is likely to be 
stronger with biallelic loss of Lkb1 as TGFß production in Lkb1–/– cells was lower than in 
Lkb1+/– cells. Accordingly, polyposis in Lkb1lox/lox;TaglnCre/+ mice was more sever than in 
Lkb1lox/+;TaglnCre/+ mice, but the increase was too small to indicate a requirement for Lkb1 
LOH. 
The mechanism of LKB1 mediated TGFß regulation is of great interest. Possible involvement 
of the known LKB1 substrates needs to be investigated in this regard for example by the 
means of RNA interference. Moreover, comparative expression profiling of normal 
gastrointestinal tissues, and polyps resulting from mesenchymal Lkb1 deletion or 
“conventional” Lkb1+/– heterozygosity, could in addition to mesenchymal TGFß regulation 
elucidate what are the epithelial transcriptional responses critical for proliferation and polyp 
development.  
 
 
LKB1 tumor suppression in Peutz-Jeghers syndrome 
 34 
CONCLUSIONS 
 
 
 
Peutz-Jeghers syndrome is a disease characterized by a devastating gastrointestinal polyposis 
and increased cancer risk. Lack of non-invasive therapy forces PJS patients to undergo 
typically multiple laparotomies due to polyposis related complications.  
This thesis work further defined the genetic background of this disease by excluding three 
PJS candidate loci whose products interact with the known PJS gene, LKB1. Results support 
the role of LKB1 as the only PJS culprit and thereby direct future studies on PJS. The results 
highlight the relevance of the findings in the Lkb1 heterozygote mouse model, as the model is 
likely to represent most if not all cases of PJS.  
Earlier observation on COX-2 induction of PJS polyps together with the dramatic results in 
other hereditary GI polyposis syndromes obtained by pharmaceutical COX-2 inhibition held 
the promise of a pharmaceutical therapy for PJS patients. The encouraging results from both 
the PJS mouse model and limited set of patients in the pilot clinical trial call for further 
studies in order to evaluate the applicability of COX-2 inhibition in PJS. Currently use of 
selective COX-2 inhibitors is however undesirable as they have been noted to increase the 
risk of cardiovascular episodes. Ongoing development of replacements for the inhibitor used 
here may allow for risk-free suppression of PJS polyp growth in the future. 
LKB1 has been suggested to be haploinsufficient as a tumor suppressor, and previous studies 
on LKB1 loss of heterozygosity have not pinpointed the cell type driving polyp development 
in PJS. The development of polyps following mesenchymal Lkb1 deletion demonstrates that 
Lkb1 is an atypical tumor suppressor controlling epithelial growth from the mesenchyme. 
Furthermore, the comparable polyposis following monoallelic and biallelic deletions of Lkb1 
indicates that Lkb1 indeed is haploinsufficient in gastrointestinal tumor suppression. The 
observation of decreased TGFß signaling after mesenchymal Lkb1 deletion links this mouse 
model with other mouse models supporting the landscaper tumor suppressor function, and 
suggests a mechanism for stromal-derived LKB1 tumor suppression.  
Considering the goal of therapy development for PJS, the results provide proof of principle 
for effectiveness of COX-2 inhibition in PJS, and serve as the basis for the development of 
therapeutic interventions targeting mesenchymal signaling in PJS polyposis and LKB1 
related cancer. 
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MATERIALS AND METHODS 
 
 
Mutation screening 
DNA prepping from whole blood samples of PJS patients without identified LKB1 mutation 
was performed using standard methods. For BRG1, 34 exons and their flanking intronic 
regions were analyzed by PCR and denaturing high-performance liquid chromatography 
(DHPLC) with automated instrumentation (Agilent Technologies). Samples demonstrating 
different DHPLC patterns from control samples were sequenced using ABI 3730 sequencer. 
The mutation screening of STRADα and MO25α was performed by genomic sequencing. 
Sequences of the used primers are available from the author upon request. Splicing 
predictions were conducted using NetGene2 splice site prediction web server 
(http://genome.cbs.dtu.dk/services/NetGene2/). 
Patients and clinical study protocol 
Patients invited to participate gave written informed consent prior to the beginning of the 
study. The study protocol was approved by the ethical board of the department of surgery at 
the University of Helsinki Central Hospital. It consisted of a gastroscopy prior to and 
following a six-month celecoxib treatment (2 x 200 mg/day). Grading of tumor burden before 
and after treatment was based on gastroscopy video recordings. Following the initial 
gastroscopies, all patients complied with the treatment regimen according to questionnaires 
made one month following onset and at the second gastroscopy. 
Gastroscopy procedures 
Gastroduodenoscopies were conducted by two endoscopists using forward-viewing video 
endoscopes (Olympus GIF Q 140, 145 or 160), on outpatient basis. When required, 
midazolam was used for sedation. During the initial endoscopy, clinically significant polyps 
(>0.5 cm in diameter) were removed before video recording from the second part of 
duodenum backwards up to the gastro-oesophageal junction. Five independent evaluators 
analyzed the video material from the gastroscopies.  
Mouse husbandry and drug administration 
All experimental mice were of mixed background. The mice had free access to food and 
water before and throughout these studies. Animal health was monitored according to the 
recommendations of the Animal Committee of the University of Helsinki. For the 
pharmacological interventions celecoxib powder (Searle-Pharmacia, Skokie, IL) was mixed 
at a concentration of 1500 parts per million with rodent chow. Tamoxifen was administered 
by intraperitoneal injections of 1 mg of 4OH-tamoxifen (Sigma) in to mice at 1.4–1.5 months 
of age, and repeated on two consecutive days. 
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Mouse genotyping  
The two strategies of targeted inactivation and genotyping of the murine Lkb1 gene have 
been described previously (Ylikorkala et al. 2001; Bardeesy et al. 2002). The generation and 
genotyping of mice with SM22-CreERt2(KI) allele has been described previously 
(Kuhbandner et al. 2000). The Cox-2 deficient strain (Dinchuk et al. 1995) was obtained from 
Jackson Laboratories (Bar Harbor, ME), and the genotyping strategy was kindly provided by 
Professor S. K. Dey (University of Vanderbilt Medical Center, Nashville, TN).  
Laser Capture Microdissection (LCM) for recombination measurements was conducted with 
Arcturus Autopix LCM-system, and DNA was purified according to manufacturers 
instructions. 
Recombination frequency of Lkb1 was measured by realtime-PCR (ABI Prism 7500, Applied 
Biosystems) using primer pairs for non-recombined (Lkb1lox) or recombined (Lkb1–) alleles. 
For this, a standard sample with a 1:1 mix of non-recombined (Lkb1lox/lox) and recombined 
(adeno-Cre infected Lkb1lox/lox) DNA was used to normalize PCR efficiency of the primer 
pairs according to 50% recombination. Subsequently the assay was validated using a series of 
DNA mixes prepared as above and DNA from tissue samples were similarly analyzed.  
Macroscopic assessment of polyps  
The small intestine and stomach of sacrificed animals were inflated with 2-4% PFA, then 
fixed with 4% PFA and 1% PFA for 1h and o/n respectively. The diameter of the polyps was 
measured using a digital micrometer and dissection microscope. Tissues were embedded and 
sectioned according to standard procedures. The PJS patient tissue samples were treated 
according to protocols of Department of Pathology, HUSLAB, Helsinki University Central 
Hospital (HUCH). 
Image analysis 
Quantitations of stainings was carried out with ImageJ software. Blue channel (counter stain) 
was omitted from RGB images to perform densitometric analysis for staining of selected 
areas or in nuclei automatically detected from images after thresholding. 
Histochemistry 
The following antibodies were used: mouse CD31, PharMingen 01950D; mouse and human 
SMA, Sigma a-5691; mouse desmin, Novocastra clone DE-R-11; mouse Ki-67, Dako 
M7249; mouse and human Phospho-SMAD2 ser465/467, Chemicon AB3849; Phospho-
ACC, Cell signaling technology #3661; phospho-S6 Cell signaling technology #2211. 
DakoCytomation ARK (K3954) kit for mouse primary antibodies was used according to 
manufacturers instructions with monoclonal antibodies raised in mouse. For CD31 
immunohistochemistry the Tyramide Signal Amplification kit (Perkin-Elmer, Boston, MA) 
was used to enhance signal. Other Immunostainings were performed according to standard 
procedures. Stainings were developed with 3, 3’ Diaminobenzidine (DAB) and slides were 
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counterstained with hematoxylin. TUNEL assay was performed with the ApopTag 
peroxidase in situ apoptosis detection kit (Chemicon/ Serologicals, Temecula, CA) according 
to manufacturers instructions. 
Cell culture 
Mouse embryonic fibroblasts (MEFs) were collected from E9.5 embryos that were minced 
into small fragments and cultured in Dulbecco's modified Eagle's medium containing 10% 
fetal calf serum, 25mM glucose, glutamine, penicillin, and streptomycin. Lymphoblast cell 
lines were prepared using standard EBV transfection methods and grown using 10% horse 
serum supplemented RPMI growth media.  
Immunoblotting and kinase assays 
Protein lysates from tissue samples were prepared in 1x Laemmli lysis buffer with FastPrep 
homogenizer (QBiogene, Carlsbad, CA). Lysates from cultured cells were either prepared in 
ELB or Laemmli lysis buffers. Protein concentrations were determined using 
spectrophotometry. Western blotting analysis using antibodies against COX-2 (160126, 
Cayman Chemical), actin (AC-40, Sigma) and p-S6 was performed as previously described 
(Rossi et al. 2002). LKB1 immunoprecipitation and kinase assays were performed as 
described (Ylikorkala et al. 1999). 
TGFß measurements  
Mink lung epithelial cells stably expressing the luciferase gene under a fragment of the PAI-1 
promoter were kindly provided by Dr. Daniel B. Rifkin (New York University School of 
Medicine, New York, NY). These cells were used to assay TGFß activity in media of 
cultured cells as previously described (Abe et al. 1994). 
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